Provided by Tiger Trade Technology Pte. Ltd.

ETF & Stock Investment

2,098.37
+13.390.64%
Number of Gainers:694
Number of Losers:312
Number of Flat:16
PE:- -
High:2,100.17
Open:2,085.26
Low:2,085.25
Close:2,084.98
Volume:4.90B
Turnover:580.93B
Market Cap:97.61T
Float Cap:91.37T

Loading ...

IPD Group Updates Market on Director Michael Sainsbury’s Equity Holdings

TIPRANKS
·
Oct 01

Piper Sandler Raises Microsoft Price Target to $610, Citing Copilot and E7 as New M365 Monetization Drivers

Deep News
·
Oct 01

Goldman Sachs pushes back second Fed rate hike forecast to December, saying need for further tightening is diminishing

Deep News
·
Oct 01

What to Eat on a Visit to Yuncheng? The "Four Dishes, One Soup and One Cake" Are a Must-Try

Deep News
·
Oct 01

Bernstein Keeps Overweight Rating on Adidas: Product Strength and Localized Operations Continue to Support Growth

Deep News
·
Oct 01

TPR Advances Share Buyback Program with Tokyo Market Purchases

TIPRANKS
·
Oct 01

West African Resources Updates Dividend Notification with Final Payment Details

TIPRANKS
·
Oct 01

RELX plc (RLXXF) Gets a Buy from Barclays

TIPRANKS
·
Oct 01

LIVE Markets-Europe Before the Bell: Futures in the Red, Semis Set for Boost

Reuters
·
Oct 01

Barclays (BARC) Gets a Buy from J.P. Morgan

TIPRANKS
·
Oct 01

Analyst Maintains Hold on Enbridge, Citing Defensive Assets but Limited Upside Amid Pipeline Competition and Balance Sheet Constraints

TIPRANKS
·
Oct 01

APN Promise signs CZK 825 million software contracts with Czech Interior Ministry

TIPRANKS
·
Oct 01

Bayer Names Christoph Koenen Chief Medical Officer

Reuters
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Oct 01

JERA Teams up with Dell, Rhaelm on AI Infrastructure Development in Japan

Reuters
·
Oct 01